SS-31 (Elamipretide)
Prescription OnlyOverview
SS-31 (Elamipretide) is a mitochondria-targeting peptide that was recently FDA-approved for Barth syndrome, making it the first disease-specific treatment for that condition. The longevity community is watching closely for broader applications. Not yet available through standard Australian prescription pathways.
Australian Scheduling
Schedule 4 (Prescription Only). FDA-approved for Barth syndrome. Not yet available through standard AU prescription pathways. Longevity applications under investigation.
Access Pathway
Not currently available through standard Australian prescription pathways. No identified AU providers. Access would require special access or clinical trial pathways.
For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.